CN106413734A - 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物 - Google Patents

用于抑制毛发生长的包含骨桥蛋白衍生物的组合物 Download PDF

Info

Publication number
CN106413734A
CN106413734A CN201580019288.XA CN201580019288A CN106413734A CN 106413734 A CN106413734 A CN 106413734A CN 201580019288 A CN201580019288 A CN 201580019288A CN 106413734 A CN106413734 A CN 106413734A
Authority
CN
China
Prior art keywords
composition
amino acid
seq
amino acids
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580019288.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.阿伦法尔
P.杜纳
A.H.尼尔森
R.波斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Follicum AB
Original Assignee
Follicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum AB filed Critical Follicum AB
Publication of CN106413734A publication Critical patent/CN106413734A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CN201580019288.XA 2014-04-17 2015-04-17 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物 Pending CN106413734A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1406989.2A GB201406989D0 (en) 2014-04-17 2014-04-17 Novel treatments
GB1406989.2 2014-04-17
PCT/GB2015/051165 WO2015159099A1 (en) 2014-04-17 2015-04-17 Compositions comprising osteopontin derivatives for the inhibition of hair growth

Publications (1)

Publication Number Publication Date
CN106413734A true CN106413734A (zh) 2017-02-15

Family

ID=50928957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580019288.XA Pending CN106413734A (zh) 2014-04-17 2015-04-17 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物

Country Status (14)

Country Link
US (1) US20170143605A1 (enExample)
EP (1) EP3131528A1 (enExample)
JP (1) JP2017513856A (enExample)
KR (1) KR20160136342A (enExample)
CN (1) CN106413734A (enExample)
AU (1) AU2015248652A1 (enExample)
BR (1) BR112016023899A2 (enExample)
CA (1) CA2945930A1 (enExample)
GB (1) GB201406989D0 (enExample)
IL (1) IL248084A0 (enExample)
MX (1) MX2016013589A (enExample)
RU (1) RU2016144971A (enExample)
SG (1) SG11201608497YA (enExample)
WO (1) WO2015159099A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545834A (zh) * 2017-05-04 2019-12-06 富力卡姆股份公司 用于治疗糖尿病的肽
CN113164548A (zh) * 2018-11-07 2021-07-23 富力卡姆股份公司 用于治疗糖尿病的肽片段
CN114007589A (zh) * 2019-04-24 2022-02-01 富力卡姆股份公司 局部制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102091567B1 (ko) * 2018-06-15 2020-03-20 인하대학교 산학협력단 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물
WO2020161255A1 (en) * 2019-02-07 2020-08-13 Dsm Ip Assets B.V. Novel method for reducing hair growth
EP3692978A1 (en) * 2019-02-07 2020-08-12 DSM IP Assets B.V. Novel method
CA3168454A1 (en) 2020-02-25 2021-09-02 David K. Rosen Compositions and methods for stimulating hair growth

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) * 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
EP1222913A1 (en) * 1999-10-21 2002-07-17 Kao Corporation Depilatories and agents for external use
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
WO2013021212A2 (en) * 2011-08-10 2013-02-14 Follicum Ab Novel compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) * 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
EP1222913A1 (en) * 1999-10-21 2002-07-17 Kao Corporation Depilatories and agents for external use
WO2001071358A1 (en) * 2000-03-23 2001-09-27 Glaxo Group Limited Method of screening for inhibitors of osteopontin
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
WO2013021212A2 (en) * 2011-08-10 2013-02-14 Follicum Ab Novel compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DA-WEN YU等: "Osteopontin Gene is Expressed in the Dermal Papilla of Pelage Follicles in a Hair-Cycle-Dependent Manner", 《THE JOURNAL OF INVESTIGATIVE DERMATOLOGY》 *
KARIN BRANNVALL等: "19-Nortestosterone influences neural stem cell proliferation and neurogenesis in the rat brain", 《EUROPEAN JOURNAL OF NEUROSCIENCE》 *
NOBUHIKO TOKURIKI等: "Stability effects of mutations and protein evolvability", 《CURRENT OPINION IN STRUCTURAL BIOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545834A (zh) * 2017-05-04 2019-12-06 富力卡姆股份公司 用于治疗糖尿病的肽
CN110545834B (zh) * 2017-05-04 2024-02-20 富力卡姆股份公司 用于治疗糖尿病的肽
CN113164548A (zh) * 2018-11-07 2021-07-23 富力卡姆股份公司 用于治疗糖尿病的肽片段
CN114007589A (zh) * 2019-04-24 2022-02-01 富力卡姆股份公司 局部制剂

Also Published As

Publication number Publication date
US20170143605A1 (en) 2017-05-25
RU2016144971A3 (enExample) 2018-11-30
KR20160136342A (ko) 2016-11-29
EP3131528A1 (en) 2017-02-22
BR112016023899A2 (pt) 2018-06-05
RU2016144971A (ru) 2018-05-17
SG11201608497YA (en) 2016-11-29
MX2016013589A (es) 2017-07-04
IL248084A0 (en) 2016-11-30
CA2945930A1 (en) 2015-10-22
JP2017513856A (ja) 2017-06-01
GB201406989D0 (en) 2014-06-04
AU2015248652A1 (en) 2016-10-20
WO2015159099A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US10517932B2 (en) Compositions and uses thereof
CN106413734A (zh) 用于抑制毛发生长的包含骨桥蛋白衍生物的组合物
US8435950B2 (en) Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same
US8877713B2 (en) Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same
CA2596597A1 (en) Method for stimulation collagen synthesis and/or kgf expression
CN105120884A (zh) 用于促进伤口愈合的短生物活性肽
US9351914B2 (en) Methods for modulating hair growth using truncated laminin-511
HK1230068A1 (en) Modified osteopontin peptides having an inactivated rgd domain and uses thereof
Class et al. Patent application title: Methods for Modulating Hair Growth Using Truncated Laminin-511 Inventors: M. Peter Marinkovich (Redwood City, CA, US) Jing Gao (Mountain View, CA, US) Xiaoyu Xu (Foster City, CA, US) Jayakumar Rajadas (Cupertino, CA, US) Jayakumar Rajadas (Cupertino, CA, US)
HK1230068B (en) Modified osteopontin peptides having an inactivated rgd domain and uses thereof
CN107405506A (zh) R‑脊椎蛋白激动剂介导的毛发生长

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170215

WD01 Invention patent application deemed withdrawn after publication